基本信息
浏览量:192
职业迁徙
个人简介
The Giacomini research group focuses on expanding our understanding of membrane transporters. Membrane transporters are of great pharmacological importance, as they play a major role in drug efficacy by regulating drug disposition and distribution. Major questions addressed in the laboratory include: What is the in vivo role of membrane transporters in drug disposition and response? How does genetic variation in membrane transporters affect clinical drug response? What is the endogenous role of membrane transporters? And, what are the structural determinants of specificity?
As PI of the NIH-funded Pharmacogenomics of Membrane Transporters project, Dr. Kathy Giacomini is leading an effort to determine the clinical implications of specific genetic variants in over 100 membrane transporters. Project ventures, ranging from basic discovery to clinical studies, have demonstrated that common variants of membrane transporters contribute to differences in drug response in ethnically diverse populations. Ultimately, these studies will increase our knowledge of the genetic basis underlying drug response, and will contribute to advancing the era of personalized medicine. Furthermore, our studies will elucidate the genetic mechanisms of decreased drug response and, ultimately, contribute to improving drug design for safe and effective treatments of subgroups of patients who do not respond to standard treatments.
Research in the laboratory focuses on drugs used in the treatment of diseases associated with metabolic syndrome. We are particularly interested in two key therapeutic agents, allopurinol, first-line medical therapy for gout and high uric acid levels, and the anti-diabetic drug, metformin, one of the world’s most widely prescribed drugs. In particular, our research focuses on discovering functional genetic variants that underlie variation in response to these drugs in large ethnically diverse patient populations. As a co-leader of the international MetGen consortium with over 10,000 patients from Europe and the U.S. on metformin, Giacomini and her collaborators are seeking to discover genetic factors that contribute to poor response to metformin. Importantly, her group is interested in understanding the molecular mechanisms responsible for metformin’s pharmacologic action. For allopurinol, we have discovered that genetic variants in membrane transporters contribute to variation in response to allopurinol. We are now seeking to understand the mechanisms through which the variants act on allopurinol response.
Finally, Kathy Giacomini and her collaborator, Russ Altman of Stanford University are the Co-PIs of the UCSF–Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI) funded by the Food and Drug Administration (FDA). Established in 2014, the UCSF-Stanford CERSI aims to advance the field of regulatory sciences and improve the development and evaluation of diagnostics, therapeutics and medical devices. The UCSF-Stanford CERSI is the first FDA funded CERSI on the west coast and seeks to address key challenges related to education and research that will advance the discovery and development of medical products.
研究兴趣
论文共 541 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jasmine Chiat Ling Ong, Benjamin Jun Jie Seng, Jeren Zheng Feng Law,Lian Leng Low,Andrea Lay Hoon Kwa,Kathleen M. Giacomini,Daniel Shu Wei Ting
Nature Reviews Drug Discoverypp.1-26, (2024)
Clinical pharmacology and therapeuticsno. 2 (2024): 169-172
Swati S. More,Melissa Itsara, Xiaodong Yang, Ethan G. Geier, Michelle K. Tadano,Youngho Seo,Henry F. VanBrocklin,William A. Weiss,Sabine Mueller,Daphne A. Haas-Kogan,Steven G. DuBois,Katherine K. Matthay,
crossref(2023)
Clinical pharmacology and therapeuticsno. 1 (2023): 11-14
Shuzhong Zhang,Katherine S. Lovejoy,James E. Shima, Leah L. Lagpacan,Yan Shu,Anna Lapuk, Ying Chen, Takafumi Komori,Joe W. Gray, Xin Chen, Stephen J. Lippard,Kathleen M. Giacomini
crossref(2023)
Matthew E Michel,Christopher C Wen,Sook Wah Yee,Kathleen M Giacomini,Amro Hamdoun,Sascha C T Nicklisch
Clinical pharmacology and therapeutics (2023)
引用0浏览0WOS引用
0
0
Clinical pharmacology and therapeuticsno. 5 (2023): 945-947
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn